{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:39:29Z","timestamp":1787009969166,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      The standard dose of imatinib for the treatment of chronic-phase chronic myeloid leukemia (CML) is 400 mg\u00b7d\n                      <jats:sup>\u22121<\/jats:sup>\n                      . A predose plasma imatinib concentration of &gt;1 mg\u00b7L\n                      <jats:sup>\u22121<\/jats:sup>\n                      is associated with improved clinical response. This study aimed to assess the plasma imatinib and norimatinib concentrations attained in patients with chronic myeloid leukemia administered standard doses of imatinib adjusted for dose, age, sex, body weight, and response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We evaluated data from a cohort of patients treated between 2008 and 2014 with respect to dose, age, sex, body weight, and response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study comprised 438 samples from 93 patients (54 male, 39 female). The median imatinib dose was 400 mg\u00b7d\n                      <jats:sup>\u22121<\/jats:sup>\n                      in men and in women. The plasma imatinib concentration ranged 0.1\u20135.0 mg\u00b7L\n                      <jats:sup>\u22121<\/jats:sup>\n                      and was below 1 mg\u00b7L\n                      <jats:sup>\u22121<\/jats:sup>\n                      in 20% and 16% of samples from men and women, respectively. The mean dose normalized plasma imatinib and norimatinib concentrations were significantly higher in women in comparison with men. This was partially related to body weight. Mixed effects ordinal logistic regression showed no evidence of an association between sex and plasma imatinib (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.13). However, there was evidence of an association between sex and plasma norimatinib, with higher norimatinib concentrations more likely in women than in men (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Imatinib therapeutic drug monitoring only provides information on dosage adequacy and on short-term adherence; longer-term adherence cannot be assessed. However, this analysis revealed that approximately 1 in 5 samples had a plasma imatinib concentration &lt;1 mg\u00b7L\n                      <jats:sup>\u22121<\/jats:sup>\n                      , which was suggestive of inadequate dosage and\/or poor adherence and posed a risk of treatment failure. Higher imatinib exposure in women may be a factor in the increased rate of long-term, stable, deep molecular response (undetectable breakpoint cluster-Abelson (BCR-ABL) transcript levels with a PCR sensitivity of 4.5 log, MR4.5) reported in women.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000440","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T17:03:53Z","timestamp":1501607033000},"page":"499-504","source":"Crossref","is-referenced-by-count":15,"title":["Women Administered Standard Dose Imatinib for Chronic Myeloid Leukemia Have Higher Dose-Adjusted Plasma Imatinib and Norimatinib Concentrations Than Men"],"prefix":"10.1097","volume":"39","author":[{"given":"Sarah L.","family":"Belsey","sequence":"first","affiliation":[{"name":"Toxicology Unit, Department of Clinical Biochemistry, King's College Hospital NHS Foundation Trust;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Ireland","sequence":"additional","affiliation":[{"name":"Department of Haematology, King's College London NHS Foundation Trust; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Haematology, King's College London NHS Foundation Trust; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aytug","family":"Kizilors","sequence":"additional","affiliation":[{"name":"Department of Haematology, King's College London NHS Foundation Trust; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aloysius","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Haematology, King's College London NHS Foundation Trust; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam J.","family":"Mufti","sequence":"additional","affiliation":[{"name":"Department of Haematology, King's College London NHS Foundation Trust; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bisquera","sequence":"additional","affiliation":[{"name":"Statistician, Department of Primary Care and Public Health Sciences, King's College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"De Lavallade","sequence":"additional","affiliation":[{"name":"Department of Haematology, King's College London NHS Foundation Trust; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Toxicology Unit, Department of Clinical Biochemistry, King's College Hospital NHS Foundation Trust;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/FTD.0b013e31823cdec9","article-title":"The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors","volume":"34","author":"Teng","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat Rev."},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2009.26.5785","article-title":"Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib","volume":"28","author":"Yoo","year":"2010","journal-title":"J Clin Oncol."},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br J Clin Pharmacol."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00280-014-2599-1","article-title":"Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualisation: results from a randomised clinical trial","volume":"74","author":"Gotta","year":"2014","journal-title":"Cancer Chemother Pharmacol."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3892\/ol.2016.4780","article-title":"Therapeutic drug monitoring and tyrosine kinase inhibitors (review)","volume":"12","author":"Herviou","year":"2016","journal-title":"Oncol Lett."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00946.x","article-title":"Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes","volume":"161","author":"Nebot","year":"2010","journal-title":"Br J Pharmacol."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/bmc.2796","article-title":"Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib","volume":"27","author":"Birch","year":"2013","journal-title":"Biomed Chromatogr."},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","article-title":"Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib","volume":"80","author":"Gardner","year":"2006","journal-title":"Clin Pharmacol Ther."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/aps.2010.79","article-title":"Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients","volume":"31","author":"Li","year":"2010","journal-title":"Acta Pharmacol Sin."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12185-009-0315-4","article-title":"Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia","volume":"89","author":"Kawaguchi","year":"2009","journal-title":"Int J Hematol."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6601152","article-title":"Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukemia","volume":"89","author":"O'Brien","year":"2003","journal-title":"Br J Cancer."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood."},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"8308","DOI":"10.1158\/1078-0432.CCR-08-1303","article-title":"Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC","volume":"14","author":"van Erp","year":"2008","journal-title":"Clin Cancer Res."},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1349-7006.2010.01643.x","article-title":"Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study","volume":"101","author":"Ishikawa","year":"2010","journal-title":"Cancer Sci."},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000324900","article-title":"Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase","volume":"87","author":"Takahashi","year":"2011","journal-title":"Pharmacology"},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/fcp.12007","article-title":"Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory","volume":"27","author":"Bouchet","year":"2013","journal-title":"Fundam Clin Pharmacol."},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol Pharm Bull."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol."},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood."},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/bjh.13649","article-title":"Sex correlates with differences in long-term outcome in chronic myeloid leukemia patients treated with imatinib","volume":"173","author":"Breccia","year":"2016","journal-title":"Br J Haematol."},{"key":"R26-20230928","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ejh.12597","article-title":"Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia","volume":"96","author":"Lin","year":"2016","journal-title":"Eur J Haematol."},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1007\/s00277-015-2315-1","article-title":"Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization","volume":"94","author":"Cross","year":"2015","journal-title":"Ann Hematol."},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00216-012-5970-2","article-title":"An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry","volume":"403","author":"Couchman","year":"2012","journal-title":"Anal Bioanal Chem."},{"key":"R30-20230928","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clml.2016.02.040","article-title":"Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib","volume":"16","author":"Unnikrishnan","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin."},{"key":"R32-20230928","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.leukres.2013.07.003","article-title":"Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors","volume":"38","author":"Efficace","year":"2014","journal-title":"Leuk Res."},{"key":"R33-20230928","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"R34-20230928","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol."},{"key":"R35-20230928","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ajh.23180","article-title":"Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am J Hematol."},{"key":"R36-20230928","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood."},{"key":"R37-20230928","doi-asserted-by":"crossref","first-page":"9455","DOI":"10.1007\/s00216-013-7361-8","article-title":"A novel approach to quantitative LC-MS\/MS: therapeutic drug monitoring of clozapine and norclozapine using isotopic internal calibration","volume":"405","author":"Couchman","year":"2013","journal-title":"Anal Bioanal Chem."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201710000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T18:43:33Z","timestamp":1719341013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201710000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000440","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}